Toyota|$17.68 (¥2,828)+1.25%▲ (in JPY terms)
Sony|$27.21 (¥4,353)+1.68%▲ (in JPY terms)
SoftBank|$22.20 (¥3,551)-5.00%▼ (in JPY terms)
MUFG|$21.84 (¥3,493)-0.14%▼ (in JPY terms)
Keyence|$468.69 (¥74,970)-0.08%▼ (in JPY terms)
Nintendo|$54.96 (¥8,791)+2.66%▲ (in JPY terms)
NTT|$1.05 (¥169)+0.72%▲ (in JPY terms)
Takeda|$42.99 (¥6,876)+0.75%▲ (in JPY terms)
Tokyo Electron|$59.41 (¥9,503)+2.14%▲ (in JPY terms)
Recruit|$110.34 (¥17,650)+5.59%▲ (in JPY terms)
ITOCHU|$15.08 (¥2,413)+0.00%▲ (in JPY terms)
Honda|$11.44 (¥1,830)+0.99%▲ (in JPY terms)
Shin-Etsu|$35.61 (¥5,696)-1.64%▼ (in JPY terms)
Tokio Marine|$3.74 (¥598)+0.64%▲ (in JPY terms)
Fast Retailing|$514.33 (¥82,270)+2.59%▲ (in JPY terms)
Toyota|$17.68 (¥2,828)+1.25%▲ (in JPY terms)
Sony|$27.21 (¥4,353)+1.68%▲ (in JPY terms)
SoftBank|$22.20 (¥3,551)-5.00%▼ (in JPY terms)
MUFG|$21.84 (¥3,493)-0.14%▼ (in JPY terms)
Keyence|$468.69 (¥74,970)-0.08%▼ (in JPY terms)
Nintendo|$54.96 (¥8,791)+2.66%▲ (in JPY terms)
NTT|$1.05 (¥169)+0.72%▲ (in JPY terms)
Takeda|$42.99 (¥6,876)+0.75%▲ (in JPY terms)
Tokyo Electron|$59.41 (¥9,503)+2.14%▲ (in JPY terms)
Recruit|$110.34 (¥17,650)+5.59%▲ (in JPY terms)
ITOCHU|$15.08 (¥2,413)+0.00%▲ (in JPY terms)
Honda|$11.44 (¥1,830)+0.99%▲ (in JPY terms)
Shin-Etsu|$35.61 (¥5,696)-1.64%▼ (in JPY terms)
Tokio Marine|$3.74 (¥598)+0.64%▲ (in JPY terms)
Fast Retailing|$514.33 (¥82,270)+2.59%▲ (in JPY terms)

2026-08-20 Shiseido Company,Limited “A highly anticipated product that sold out immediately after its release on August 20, 2026*! Revital's eye pack, which provides under-eye bag care with a "pseudo-skin film that you apply," is finally back in stock!”

2026-08-20 Shiseido Company,Limited “A highly anticipated product that sold out immediately after its re … 続きを読む

2026-08-20 Otsuka Holdings Co.,Ltd. “Zipalertinib Plus Chemotherapy First-Line Phase 3 REZILIENT3 Trial Data Selected for Presidential Symposium Presentation at the IASLC 2026 World Conference on Lung Cancer (Link to Taiho Oncology's English page).”

2026-08-20 Otsuka Holdings Co.,Ltd. “Zipalertinib Plus Chemotherapy First-Line Phase 3 REZILIENT3 Trial … 続きを読む